Abpro/Celltrion present top-ranked preclinical data for CT-P72/ABP-102 at SITC 2025

Abpro Holdings, Inc.

Poster selected as Top 150 abstract out of >1,300 submissions at SITC 2025.
CT-P72/ABP-102 shows potent anti-tumor activity in HER2-high models including Enhertu-resistant tumors.
Dual-affinity engineering reduces off-tumor activation; favorable safety in monkeys up to 90 mg/kg.
Data supports advancement toward first-in-human trial planned for next year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.